08:18 AM EDT, 10/28/2025 (MT Newswires) -- Merck ( MRK ) said Tuesday that a phase 3 study of Keytruda in combination with Welireg to treat patients with clear cell renal cell carcinoma following nephrectomy met the study's primary endpoint.

The study met the primary endpoint of disease-free survival compared with Keytruda in combination with placebo, the drugmaker said, adding that the trial will continue to evaluate a key secondary endpoint of overall survival.

Merck ( MRK ) also said the safety profiles of Keytruda plus Welireg were consistent with those reported in previous studies for the therapies.